Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

Abstract : Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then bevacizumab or chemotherapy at recurrence (N = 265). Bevacizumab use increased median overall survival (OS) 18.7 vs 11.3 months, p = 0.0014). In multivariate analysis, age, initial surgery, neutrophil count, Karnofsky status > 70% and bevacizumab administration were independent prognostic factors of survival. We found an interaction between bevacizumab use and baseline neutrophil count. The cut-off value for the neutrophil count was set at 6000/mm(3). Only patients with a high neutrophil count benefited from the bevacizumab treatment (17.3 vs 8.8 months p < 0.0001). We validated this result using data from the TEMAVIR trial, which tested the efficacy of neoadjuvant bevacizumab plus irinotecan versus radiochemotherapy in the first-line treatment of glioblastoma. Transcriptomic data from TCGA underlined that CSF3 expression, the gene encoding G-CSF, the growth factor for neutrophils, correlated with VEGF-A-dependent angiogenesis. In another independent cohort (BELOB trial), which compared lomustine versus lomustine plus bevacizumab at recurrence, bevacizumab only benefited patients with high CSF3 expression in the tumor. These data suggest that only patients with a high peripheral neutrophil count before bevacizumab treatment benefited from this therapy.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01410048
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : mardi 6 décembre 2016 - 12:57:46
Dernière modification le : mercredi 14 octobre 2020 - 04:08:04

Lien texte intégral

Identifiants

Citation

Aurélie Bertaut, Caroline Truntzer, Rachid Madkouri, Coureche Guillaume Kaderbhai, Valentin Derangère, et al.. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget, Impact journals, 2016, 7 (43), pp.70948-70958. ⟨10.18632/oncotarget.10898⟩. ⟨hal-01410048⟩

Partager

Métriques

Consultations de la notice

312